Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

• Main Authors: Jennifer Soung (Author), Sonja Ständer (Author), Jan Gutermuth (Author), Ignasi Pau-Charles (Author), Zach Dawson (Author), Fan Emily Yang (Author), Luna Sun (Author), Evangeline Pierce (Author), Hany Elmaraghy (Author), Linda Stein-Gold (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AbstractBackground Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch and sleep interference due to itch and t...